Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.69 |
| ▸ | TNF | P01375 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127722 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4847439 | 0.90 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4851023 | 0.90 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4925142 | 0.88 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3131798 | 0.87 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4852155 | 0.87 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4847349 | 0.87 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3131810 | 0.86 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6099727 | 0.85 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537107 | 0.84 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2008-11-13 | — | — | US | claimed |
| US-7345062-B2 | Substituted acylhydroxamic acids and method of reducing TNFαlevels | CELGENE CORPORATION (US) | 2008-03-18 | — | — | US | claimed |
| US-6699899-B1 | ISOINDOLE DERIVATIVES; ANTIINFLAMMATORY, ANTIPYRETIC, AND ANTICOAGULANT AGENTS | CELGENE CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2008-11-13 | — | — | US | disclosed |
| US-7345062-B2 | Substituted acylhydroxamic acids and method of reducing TNFαlevels | CELGENE CORPORATION (US) | 2008-03-18 | — | — | US | disclosed |
| US-6699899-B1 | ISOINDOLE DERIVATIVES; ANTIINFLAMMATORY, ANTIPYRETIC, AND ANTICOAGULANT AGENTS | CELGENE CORPORATION | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | APEH, TNF, ACOX3 | PDE4A 30/4885PDE4B 70/4885PDE4C 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.